leadf
logo-loader
viewTetra Bio-Pharma

Tetra Bio-Pharma new CFO discusses recent pipeline advancements and company updates

Tetra Bio-Pharma Inc (TSE:TBP)(OTCQB:TBPMF) CFO Jean-François Boily tells Proactive how the leader in cannabinoid-derived drug discovery is progressing on some of its advancing programs.

Boily says the group completed mapping of human cannabinoids and metabolites during the third quarter of 2020, adding that this milestone has a major impact on both its QIXLEEF and CAUMZ drug development programs.

Quick facts: Tetra Bio-Pharma

Price: 0.195 CAD

TSX:TBP
Market: TSX
Market Cap: $54.96 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Tetra Bio-Pharma named herein, including the promotion by the Company of Tetra Bio-Pharma in any Content on the Site, the Company receives from...

FOR OUR FULL DISCLAIMER CLICK HERE

Tetra Bio-Pharma makes progress with inhaled THC-based drug in meeting with...

Tetra Bio-Pharma Inc (TSE:TBP) (OTCQB:TBPMF) (FRA:JAM1) CEO Guy Chamberland tells Proactive the group it held a Type B meeting with the FDA for an inhaled THC-based innovative drug for the treatment of chemotherapy-induced nausea and vomiting (CINV). Chamberland says new drug will be part its...

on 16/12/20

2 min read